Mylan Nv Ord Shs (MYL) 46.16 $MYL
Mylan Donates EUR 1 Million to the Princess Máxima Center for Pediatric Oncology
PR Newswire - Thu Jun 23, 10:22AM CDT
Mylan N.V. (NASDAQ, TASE: MYL), one of the world's leading pharmaceutical companies, today announced a EUR 1 million donation to the Princess Máxima Center for Pediatric Oncology, a new national cancer center currently being built in Utrecht, the Netherlands.
MYL: 46.16 (+1.16)
Mylan Falls 1.61% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:58PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.06 to a high of $45.79. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $44.09 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.16 (+1.16)
Attorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction
PR Newswire - Mon Jun 20, 8:54AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the Attorney General of the Netherlands has rejected the request of the Dutch group VEB to initiate enquiry proceedings at the Enterprise Chamber of the Amsterdam Court of Appeal in respect of VEB's opinion that Mylan's shareholders should approve its recently announced public offer for all shares in Meda Aktiebolag (publ.). Mylan has consistently communicated to the VEB and to its shareholders that under applicable law such shareholder approval is not required.
MYL: 46.16 (+1.16)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.15 (-0.01), AGN: 233.51 (+4.96), HZNP: 17.44 (+0.66), MYL: 46.16 (+1.16)
Mylan to Commence Meda Offer on June 17
PR Newswire Europe - Thu Jun 16, 3:35PM CDT
Mylan's Offer Document Approved and Published
MYL: 46.16 (+1.16)
Mylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business
PR Newswire - Wed Jun 15, 12:47PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has successfully completed the acquisition of the non-sterile, topicals-focused specialty and generics business (the "Business"
of Renaissance Acquisition Holdings, LLC ("Renaissance".
MYL: 46.16 (+1.16)
ConocoPhillips, Citigroup and Mattress Firm stumble
AP - Fri Jun 10, 3:39PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
URBN: 26.90 (-0.07), GBT: 16.74 (-0.82), AXLL: 32.67 (+0.22), C: 44.46 (+1.78), MYL: 46.16 (+1.16), WFC: 47.91 (+0.94), MFRM: 33.37 (-0.98), HRB: 22.85 (+0.25)
After Yesterday's Decline of 3.04%, Mylan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 10, 12:56PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.16 (+1.16)
SmarTrend Watching for Potential Rebound in Shares of Mylan After 3.04% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:54PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.16 (+1.16)
Mylan Becomes #21 Most Shorted Nasdaq 100 Component, Replacing Akamai Technologies
MarketNewsVideo.com - Fri Jun 10, 12:43PM CDT
The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a...
MYL: 46.16 (+1.16)
Stock Market News for June 07, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 9:10AM CDT
Benchmarks closed in the green on Monday after the Fed Chairwoman Janet Yellen said that most of the domestic economic data were favorable and indicated rate hikes this year.
VRTX: 88.20 (+2.98), FCX: 11.77 (+0.27), ILMN: 146.59 (+5.70), XOM: 91.80 (+0.63), MYL: 46.16 (+1.16), BA: 133.55 (+1.78), SLB: 79.59 (+1.32), AA: 10.15 (+0.26), LYB: 79.05 (+0.08), RIG: 12.03 (+0.63), KITE: 53.11 (+1.97), CF: 27.64 (+0.62), CHK: 4.64 (+0.13), EOG: 84.50 (+0.90), CVX: 104.44 (+2.15), ECL: 120.94 (+1.50)
Mylan Rises 3.46% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jun 06, 1:51PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.16 (+1.16)
Watch for Mylan to Potentially Pullback After Gaining 3.46% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 1:50PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.16 (+1.16)
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Fri Jun 03, 1:00PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of data from the HERITAGE study at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7. The study confirmed the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Biocon and Mylan, in comparison to branded trastuzumab.
MYL: 46.16 (+1.16)
Mylan Launches Generic Cleocin® Solution
PR Newswire - Fri Jun 03, 9:56AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Clindamycin Palmitate Hydrochloride for Oral Solution USP, 75 mg/5 mL, which is a generic version of Pharmacia and Upjohn's Cleocin® Solution. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives are inappropriate.(1)
MYL: 46.16 (+1.16)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 46.16 (+1.16), CELGZ: 1.45 (+0.01)
Mylan Launches Generic Rythmol® Sustained-Release Capsules
PR Newswire - Thu Jun 02, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg, a generic version of GlaxoSmithKline's Rythmol® SR. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.(1)
MYL: 46.16 (+1.16), GSK: 42.56 (+0.80)
Look for Shares of Mylan to Potentially Pullback after Yesterday's 2.58% Rise
Comtex SmarTrend(R) - Wed Jun 01, 12:29PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.97 to a high of $44.86. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $43.84 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.16 (+1.16)
Watch for Mylan to Potentially Pullback After Gaining 2.58% Yesterday
Comtex SmarTrend(R) - Wed Jun 01, 12:28PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.97 to a high of $44.86. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $43.84 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.16 (+1.16)
Mylan Donates EUR 1 Million to the Princess Máxima Center for Pediatric Oncology
PR Newswire - Thu Jun 23, 10:22AM CDT
Mylan N.V. (NASDAQ, TASE: MYL), one of the world's leading pharmaceutical companies, today announced a EUR 1 million donation to the Princess Máxima Center for Pediatric Oncology, a new national cancer center currently being built in Utrecht, the Netherlands.
MYL: 46.16 (+1.16)
Mylan Falls 1.61% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:58PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.06 to a high of $45.79. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $44.09 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.16 (+1.16)
Attorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction
PR Newswire - Mon Jun 20, 8:54AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the Attorney General of the Netherlands has rejected the request of the Dutch group VEB to initiate enquiry proceedings at the Enterprise Chamber of the Amsterdam Court of Appeal in respect of VEB's opinion that Mylan's shareholders should approve its recently announced public offer for all shares in Meda Aktiebolag (publ.). Mylan has consistently communicated to the VEB and to its shareholders that under applicable law such shareholder approval is not required.
MYL: 46.16 (+1.16)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.15 (-0.01), AGN: 233.51 (+4.96), HZNP: 17.44 (+0.66), MYL: 46.16 (+1.16)
Mylan to Commence Meda Offer on June 17
PR Newswire Europe - Thu Jun 16, 3:35PM CDT
Mylan's Offer Document Approved and Published
MYL: 46.16 (+1.16)
Mylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business
PR Newswire - Wed Jun 15, 12:47PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has successfully completed the acquisition of the non-sterile, topicals-focused specialty and generics business (the "Business"
of Renaissance Acquisition Holdings, LLC ("Renaissance". MYL: 46.16 (+1.16)
ConocoPhillips, Citigroup and Mattress Firm stumble
AP - Fri Jun 10, 3:39PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
URBN: 26.90 (-0.07), GBT: 16.74 (-0.82), AXLL: 32.67 (+0.22), C: 44.46 (+1.78), MYL: 46.16 (+1.16), WFC: 47.91 (+0.94), MFRM: 33.37 (-0.98), HRB: 22.85 (+0.25)
After Yesterday's Decline of 3.04%, Mylan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 10, 12:56PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.16 (+1.16)
SmarTrend Watching for Potential Rebound in Shares of Mylan After 3.04% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:54PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.16 (+1.16)
Mylan Becomes #21 Most Shorted Nasdaq 100 Component, Replacing Akamai Technologies
MarketNewsVideo.com - Fri Jun 10, 12:43PM CDT
The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a...
MYL: 46.16 (+1.16)
Stock Market News for June 07, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 9:10AM CDT
Benchmarks closed in the green on Monday after the Fed Chairwoman Janet Yellen said that most of the domestic economic data were favorable and indicated rate hikes this year.
VRTX: 88.20 (+2.98), FCX: 11.77 (+0.27), ILMN: 146.59 (+5.70), XOM: 91.80 (+0.63), MYL: 46.16 (+1.16), BA: 133.55 (+1.78), SLB: 79.59 (+1.32), AA: 10.15 (+0.26), LYB: 79.05 (+0.08), RIG: 12.03 (+0.63), KITE: 53.11 (+1.97), CF: 27.64 (+0.62), CHK: 4.64 (+0.13), EOG: 84.50 (+0.90), CVX: 104.44 (+2.15), ECL: 120.94 (+1.50)
Mylan Rises 3.46% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jun 06, 1:51PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.16 (+1.16)
Watch for Mylan to Potentially Pullback After Gaining 3.46% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 1:50PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.16 (+1.16)
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Fri Jun 03, 1:00PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of data from the HERITAGE study at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7. The study confirmed the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Biocon and Mylan, in comparison to branded trastuzumab.
MYL: 46.16 (+1.16)
Mylan Launches Generic Cleocin® Solution
PR Newswire - Fri Jun 03, 9:56AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Clindamycin Palmitate Hydrochloride for Oral Solution USP, 75 mg/5 mL, which is a generic version of Pharmacia and Upjohn's Cleocin® Solution. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives are inappropriate.(1)
MYL: 46.16 (+1.16)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 46.16 (+1.16), CELGZ: 1.45 (+0.01)
Mylan Launches Generic Rythmol® Sustained-Release Capsules
PR Newswire - Thu Jun 02, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg, a generic version of GlaxoSmithKline's Rythmol® SR. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease.(1)
MYL: 46.16 (+1.16), GSK: 42.56 (+0.80)
Look for Shares of Mylan to Potentially Pullback after Yesterday's 2.58% Rise
Comtex SmarTrend(R) - Wed Jun 01, 12:29PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.97 to a high of $44.86. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $43.84 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.16 (+1.16)
Watch for Mylan to Potentially Pullback After Gaining 2.58% Yesterday
Comtex SmarTrend(R) - Wed Jun 01, 12:28PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.97 to a high of $44.86. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $43.84 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.16 (+1.16)
